Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that sells DNA tests, builds multi-cancer detection panels, and even secures data on the blockchain can feel overwhelming. Prenetics鈥� SEC filings blend consumer-nutrition details with highly technical genomic disclosures, making it hard to spot what truly moves the stock.
Stock Titan solves that problem. Our AI turns Prenetics鈥� 300-page annual report 10-K into a digestible brief, flags segment revenue from IM8 supplements versus Insighta diagnostics, and alerts you to Prenetics insider trading Form 4 transactions the instant they hit EDGAR. Need the latest numbers? The platform autogenerates plain-language highlights from every Prenetics quarterly earnings report 10-Q filing and attaches context so you understand R&D spend on new genomic assays.
Wondering which disclosures matter most? Browse a dedicated feed that maps each filing type to real questions investors ask:
- 10-K & 10-Q 鈥� revenue by division, regulatory milestones, liquidity trends
- 8-K material events explained 鈥� clinical-trial readouts or blockchain partnerships
- Form 4 insider transactions real-time 鈥� see if executives buy before data releases
- Proxy statement executive compensation 鈥� incentives tied to cancer-test approvals
Every document arrives with AI-powered summaries, keyword search, and cross-links鈥攕o understanding Prenetics SEC documents with AI becomes a five-minute task, not a weekend project. Whether you鈥檙e looking for a Prenetics earnings report filing analysis or need a Prenetics annual report 10-K simplified, Stock Titan keeps you ahead of the curve.
On 1 Aug 2025, Prenetics Global Limited (NASDAQ: PRE) reported the results of an Extraordinary General Meeting via Form 6-K. Shareholders approved two resolutions:
- Proposal 1 鈥� Authorised Share Capital Increase: the authorised capital rises from US$50,000 (33.3 m shares) to US$320,000 (213.3 m shares) at the unchanged par value of US$0.0015. This adds 160 m Class A shares, 12 m Class B convertible shares and 8 m undesignated shares. The motion passed with 4,250,875 votes FOR versus 503,820 AGAINST (鈮�78.7% support).
- Proposal 2 鈥� Administrative Filing Authority: authorises the company鈥檚 registered office provider to file the amended charter with Cayman authorities. Passed with 4,744,054 FOR and only 14,922 AGAINST.
No financial results were disclosed. Approval materially expands the company鈥檚 capacity to issue new equity, signalling potential future capital raises and possible dilution for existing holders.
FAQ
What is the current stock price of Prenetics (PRE)?
What is the market cap of Prenetics (PRE)?
